Head to Head Survey: Vaxart (NASDAQ:VXRT) & Black Diamond Therapeutics (NASDAQ:BDTX)

Vaxart (NASDAQ:VXRT) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Risk and Volatility

Vaxart has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Profitability

This table compares Vaxart and Black Diamond Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	-543.21%	-114.19%	-75.68%
Black Diamond Therapeutics	N/A	-69.08%	-51.68%

Insider & Institutional Ownership

18.1% of Vaxart shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 2.6% of Vaxart shares are owned by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Vaxart and Black Diamond Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$7.38 million	18.51	-$82.46 million	($0.46)	-1.67
Black Diamond Therapeutics	N/A	N/A	-$82.44 million	($1.50)	-1.93

Black Diamond Therapeutics has lower revenue, but higher earnings than Vaxart. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Vaxart and Black Diamond Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	0	2	0	3.00
Black Diamond Therapeutics	0	0	4	0	3.00

Vaxart presently has a consensus target price of $3.00, indicating a potential upside of 289.66%. Black Diamond Therapeutics has a consensus target price of $15.50, indicating a potential upside of 436.33%. Given Black Diamond Therapeutics’ higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Vaxart.

Summary

Black Diamond Therapeutics beats Vaxart on 9 of the 11 factors compared between the two stocks.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.